BRPI0922840A2 - complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos - Google Patents

complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos

Info

Publication number
BRPI0922840A2
BRPI0922840A2 BRPI0922840A BRPI0922840A BRPI0922840A2 BR PI0922840 A2 BRPI0922840 A2 BR PI0922840A2 BR PI0922840 A BRPI0922840 A BR PI0922840A BR PI0922840 A BRPI0922840 A BR PI0922840A BR PI0922840 A2 BRPI0922840 A2 BR PI0922840A2
Authority
BR
Brazil
Prior art keywords
technetium
rhenium
heteroaryl
complexes
bis
Prior art date
Application number
BRPI0922840A
Other languages
English (en)
Inventor
Craig Zimmermann
Genliang Lu
Jian-Cheng Wang
John Joyal
John Marquis
John W Babich
Kevin P Maresca
Shawn Hillier
Original Assignee
Molecular Insight Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/350,894 external-priority patent/US8877970B2/en
Application filed by Molecular Insight Pharm Inc filed Critical Molecular Insight Pharm Inc
Priority claimed from PCT/US2009/066832 external-priority patent/WO2010065899A2/en
Publication of BRPI0922840A2 publication Critical patent/BRPI0922840A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0922840A 2008-12-05 2009-12-04 complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos BRPI0922840A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12022608P 2008-12-05 2008-12-05
US12/350,894 US8877970B2 (en) 2008-01-09 2009-01-08 Inhibitors of carbonic anhydrase IX
US18034109P 2009-05-21 2009-05-21
PCT/US2009/066832 WO2010065899A2 (en) 2008-12-05 2009-12-04 Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0922840A2 true BRPI0922840A2 (pt) 2015-12-29

Family

ID=42076951

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0922779A BRPI0922779A8 (pt) 2008-12-05 2009-12-04 complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma
BRPI0922840A BRPI0922840A2 (pt) 2008-12-05 2009-12-04 complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos
BRPI0922839A BRPI0922839A2 (pt) 2008-12-05 2009-12-04 radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0922779A BRPI0922779A8 (pt) 2008-12-05 2009-12-04 complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0922839A BRPI0922839A2 (pt) 2008-12-05 2009-12-04 radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer.

Country Status (13)

Country Link
US (1) US8211401B2 (pt)
EP (4) EP2373621A2 (pt)
JP (4) JP2012511024A (pt)
CN (3) CN102272102A (pt)
AU (3) AU2009322167B2 (pt)
BR (3) BRPI0922779A8 (pt)
CA (3) CA2745958A1 (pt)
ES (2) ES2574514T3 (pt)
HU (2) HUE030681T2 (pt)
PL (2) PL2389361T3 (pt)
RU (3) RU2539565C2 (pt)
TW (3) TW201034689A (pt)
WO (1) WO2010065902A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2227784B1 (en) 2007-12-28 2014-07-16 Exini Diagnostics AB System for detecting bone cancer metastases
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
JP2011509304A (ja) 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
RU2539565C2 (ru) * 2008-12-05 2015-01-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP6275484B2 (ja) * 2010-12-06 2018-02-07 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Ｐｓｍａ標的化デンドリマー
TR201910084T4 (tr) 2011-08-05 2019-08-21 Molecular Insight Pharm Inc Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri.
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
EP2785712B1 (en) * 2011-11-30 2019-05-01 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
WO2013103813A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
FR2989085A1 (fr) * 2012-04-05 2013-10-11 Commissariat Energie Atomique Radiotraceurs, procedes de preparation et applications
EA201590783A1 (ru) * 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
BR112015016585B1 (pt) * 2013-01-14 2021-02-02 Molecular Insight Pharmaceuticals compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
JP6434496B2 (ja) * 2013-04-22 2018-12-05 アッヴィ・インコーポレイテッド チアゾールおよびその使用
CN105636924B (zh) 2013-10-18 2018-08-07 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
CN105792855A (zh) * 2013-10-18 2016-07-20 分子制药洞察公司 使用spect/ct分析进行癌症分期的方法
EP2993171A1 (en) * 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
NZ739770A (en) 2015-09-30 2019-07-26 Deutsches Krebsforsch 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN105510511B (zh) * 2016-01-23 2017-04-12 河北科技大学 一种2‑氨基丁醇对映异构体的hplc分离检测方法
US11458213B2 (en) * 2016-03-22 2022-10-04 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CA3028978A1 (en) 2016-06-23 2017-12-28 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CA3036754A1 (en) 2016-10-27 2018-05-03 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (gui) applications
CN110612126B (zh) 2017-04-05 2023-11-03 康奈尔大学 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
WO2019136349A2 (en) 2018-01-08 2019-07-11 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
US10973486B2 (en) 2018-01-08 2021-04-13 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
CA3090495A1 (en) * 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
RU2692126C1 (ru) * 2018-02-13 2019-06-21 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ получения производного мочевины с хелатным центром, тропного к простат-специфичному мембранному антигену для связывания технеция-99м/рения для диагностики/лечения рака предстательной железы
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
CN112638919A (zh) * 2018-08-30 2021-04-09 日本医事物理股份有限公司 放射性咪唑并噻二唑衍生物化合物
CN113272859A (zh) 2019-01-07 2021-08-17 西尼诊断公司 用于平台中立性全身图像分段的系统及方法
US11534125B2 (en) 2019-04-24 2022-12-27 Progenies Pharmaceuticals, Inc. Systems and methods for automated and interactive analysis of bone scan images for detection of metastases
CA3134745A1 (en) 2019-04-24 2020-10-29 Progenics Pharmaceuticals, Inc. Systems and methods for interactive adjustment of intensity windowing in nuclear medicine images
US11544407B1 (en) 2019-09-27 2023-01-03 Progenics Pharmaceuticals, Inc. Systems and methods for secure cloud-based medical image upload and processing
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11564621B2 (en) 2019-09-27 2023-01-31 Progenies Pharmacenticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11386988B2 (en) 2020-04-23 2022-07-12 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
US11321844B2 (en) 2020-04-23 2022-05-03 Exini Diagnostics Ab Systems and methods for deep-learning-based segmentation of composite images
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
TW202207241A (zh) 2020-07-06 2022-02-16 瑞典商艾西尼診斷公司 用於偵測及表徵化病變之基於人工智慧的影像分析系統與方法
EP4326246A1 (en) * 2021-04-23 2024-02-28 Wisconsin Alumni Research Foundation Psma-targeting ligands with optimal properties for imaging and therapy
WO2023057411A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
WO2023239829A2 (en) 2022-06-08 2023-12-14 Progenics Pharmaceuticals, Inc. Systems and methods for assessing disease burden and progression
US20240285248A1 (en) 2023-02-13 2024-08-29 Progenics Pharmaceuticals, Inc. Systems and methods for predicting biochemical progression free survival in prostate cancer patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JP3051497B2 (ja) 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
HUT66220A (en) * 1991-12-10 1994-10-28 Dow Chemical Co Bicyclopolyazamacrocyclophosponic acids, their complexes and conjugates for use as contrast agents, and processes for their preparation
ES2200617B1 (es) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
EP1389460A1 (en) * 2001-05-24 2004-02-18 Kureha Chemical Industry Co., Ltd. Cxcr4-antagonistic drugs comprising nitrogen-containing compound
DE10127581A1 (de) * 2001-05-29 2003-01-02 Schering Ag CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2003053932A1 (fr) * 2001-12-21 2003-07-03 Tohru Koike Complexes de zinc capables de pieger des substances portant des substituants anioniques
CA2372731A1 (en) * 2002-02-22 2003-08-22 Claudiu T. Supuran Oligo-amine/oligo-carboxy sulfonamides
AU2003213819C1 (en) 2002-03-11 2010-03-04 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
KR100863667B1 (ko) * 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
CA2506983C (en) 2002-11-26 2010-03-30 Institute Of Virology Ca ix-specific inhibitors
US7291631B2 (en) * 2003-04-11 2007-11-06 Genzyme Corporation CXCR4 chemokine receptor binding compounds
EP1692099A1 (en) 2003-12-12 2006-08-23 Oy Juvantia Pharma Ltd Somatostatine receptor subtype 1 (sstr1) active compounds and their use in therapy
AU2005215510A1 (en) * 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
KR101149124B1 (ko) * 2004-03-10 2012-05-25 가부시끼가이샤 구레하 아민계 염기성 화합물과 그의 용도
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
WO2006137092A1 (en) * 2005-06-23 2006-12-28 Supuran Claudiu T Fluorescent sulfonamide derivatives having carbonic anhydrase inhibiting activity and their use as theapeutic and diagnostic agents
FR2890657B1 (fr) * 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
WO2007058322A1 (ja) * 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
US20090044345A1 (en) 2006-02-06 2009-02-19 Gunther Schlingloff Use of Metal Complex Compounds as Oxidation Catalysts
EP2030971B1 (en) 2006-06-20 2011-10-12 Ishihara Sangyo Kaisha, Ltd. Pest control agent containing novel pyridyl-methanamine derivative or salt thereof
EP2055705A4 (en) * 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
CN101594886A (zh) * 2006-08-29 2009-12-02 分子制药洞察公司 偶合到用于成像表达肽酶的组织和器官的肽酶结合部分的放射影像部分
EP3335736B1 (en) * 2006-11-08 2020-12-30 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
WO2008098056A2 (en) * 2007-02-06 2008-08-14 Epix Pharmaceuticals, Inc. High relaxivity chelates
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
US8562945B2 (en) * 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
JP2011509304A (ja) * 2008-01-09 2011-03-24 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 炭酸脱水酵素ｉｘの阻害剤
US20100098633A1 (en) 2008-09-25 2010-04-22 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
RU2539565C2 (ru) * 2008-12-05 2015-01-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer

Also Published As

Publication number Publication date
EP2389361B1 (en) 2016-08-24
CA2745958A1 (en) 2010-06-10
AU2009322164B2 (en) 2014-12-18
CN102272102A (zh) 2011-12-07
AU2009322167A1 (en) 2011-07-07
PL2389361T3 (pl) 2017-02-28
HUE030681T2 (en) 2017-05-29
JP5856247B2 (ja) 2016-02-09
BRPI0922839A2 (pt) 2019-09-03
AU2009322164A1 (en) 2011-06-30
JP2014240394A (ja) 2014-12-25
CN102272100A (zh) 2011-12-07
US8211401B2 (en) 2012-07-03
RU2539584C2 (ru) 2015-01-20
HUE029940T2 (en) 2017-04-28
ES2574514T3 (es) 2016-06-20
AU2009322167B2 (en) 2014-11-20
CA2745918A1 (en) 2010-06-10
TW201034691A (en) 2010-10-01
RU2532912C2 (ru) 2014-11-20
PL2706057T3 (pl) 2016-10-31
US20100178246A1 (en) 2010-07-15
EP2373621A2 (en) 2011-10-12
CA2745955C (en) 2017-05-23
BRPI0922779A2 (pt) 2017-07-11
CN102272100B (zh) 2016-08-17
EP2389361A2 (en) 2011-11-30
WO2010065902A2 (en) 2010-06-10
EP2759535A1 (en) 2014-07-30
WO2010065902A3 (en) 2011-02-17
CN102272101A (zh) 2011-12-07
EP2373622A2 (en) 2011-10-12
JP5220203B2 (ja) 2013-06-26
CA2745955A1 (en) 2010-06-10
TW201034690A (en) 2010-10-01
JP2012511023A (ja) 2012-05-17
TW201034689A (en) 2010-10-01
AU2009322171A1 (en) 2011-06-30
BRPI0922779A8 (pt) 2018-06-19
JP2012511024A (ja) 2012-05-17
JP2012511022A (ja) 2012-05-17
RU2539565C2 (ru) 2015-01-20
CA2745918C (en) 2017-10-10
ES2595128T3 (es) 2016-12-27

Similar Documents

Publication Publication Date Title
BRPI0922840A2 (pt) complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos
BRPI0822229A2 (pt) Coacervados de complexos adesivo e métodos de fabricação e uso dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0909077A2 (pt) Artigos multicamadas e métodos de preparo e uso dos mesmos
BRPI0821499A2 (pt) Artigos de filtração de fluído e métodos de preparo e uso dos mesmos
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BR112012024120A2 (pt) sarms e método de uso dos mesmos
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI0815811A2 (pt) Derivados de indol substituído e métodos de uso dos mesmos
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BR112013014321A2 (pt) moduladores inovadores e métodos de uso
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI0915300A2 (pt) composto de éster boronato e composições farmaceuticas dos mesmos
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0921983A2 (pt) moduladores tgr5 e métodos de uso dos mesmos
DOP2010000260A (es) Derivado heterociclico fusionado y su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2009, OBSERVADAS AS CONDICOES LEGAIS